ArticleFrontiers in oncology2025
Demographic/clinicopathological characteristics and prognosis of resectable Epstein-Barr virus-associated gastric cancer: a nested case-control study from an Eastern China.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Postoperative Adjuvant Treatment Decision for Early Epstein-Barr Virus-Associated Gastric Cancer.Journal of medical cases · 2026Article
- Epstein-Barr Virus-Mediated Apoptosis Evasion in Epithelial Malignancies: Molecular Mechanisms and Therapeutic Implications.Biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Epstein-Barr virus-associated gastric cancer (EBVaGC) represents a distinct molecular subtype of gastric cancer (GC). This multicenter study aimed to investigate the clinicopathological characteristics and prognosis of resectable EBVaGC patients. Methods: Data were prospectively collected and retrospectively analyzed from 1,400 patients at Ningbo No. 2 Hospital from January 2014 to December 2023 and 55 EBVaGC patients were identified. Additionally, 95 EBVaGC patients from two external cooperative centers were included. A 1:4 propensity score matching (PSM) analysis was performed between EBVaGC patients and EBV-negative gastric cancer (EBVnGC) patients. Median follow-up duration was 34 months. Results: Among the 150 EBVaGC patients, the median age was 64, and 88.7% were male. Undifferentiated tumors were more common. During the follow-up, 121 EBVaGC patients did not experience recurrence. After PSM, there were 137 EBVaGC patients and 548 EBVnGC patients. In EBVaGC patients, elevated Carcinoembryonic Antigen (CEA) levels (HR = 8.11, p=0.025) and pathological tumor-node-metastasis (pTNM) stage III (HR = 19.57, p=0.008) were independent risk factors for overall survival (OS). For disease-free survival (DFS), elevated CEA levels (HR = 6.23, p=0.035) and pTNM stage III (HR = 18.51, p=0.007) were independent risk factors. There was no significant difference in OS between the two groups (p=0.204). Compared to EBVnGC patients, EBVaGC patients showed a trend towards better DFS, although this did not reach statistical significance(p=0.061). Conclusion: EBVaGC patients exhibit unique clinicopathological characteristics and may show a trend toward better prognosis compared with EBVnGC patients, although this difference did not reach statistical significance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.